Reven Holdings announces first patient dosed in clinical trial evaluating RJX for high-risk COVID-19
WESTMINSTER -- Reven Holdings, Inc. today announced the first patient has been dosed in the Phase I/II trial of RJX in high-risk COVID-19 patients ( ClinicalTrials.gov Identifier: NCT04708340; ... Read More
Thursday April 29, 2021
Reven Pharmaceuticals reports positive results regarding clinical safety and preclinical efficacy of Its COVID-19 drug candidate Rejuveinix
GOLDEN -- Reven Holdings, Inc. today announced publication of a peer-reviewed article in the prestigious medical journal, Frontiers in Pharmacology, Section: Respiratory Pharmacology. In the... Read More
Thursday November 12, 2020
Reven Pharmaceuticals wins FDA nod of IND application for COVID treatment with Rejuveinix
GOLDEN -- Reven today announced the U.S. Food and Drug Administration has approved its Investigational New Drug application in connection with its lead anti-inflammatory/anti-oxidant... Read More
Thursday October 22, 2020
Reven selects eClinical services provider DSG to accelerate Reven’s RJX as treatment for COVID-19
GOLDEN -- Reven Holdings, Inc. today announced it selected DSG, Inc., a leading global eClinical services provider, for all aspects of clinical trial data management during its upcoming COVID-19... Read More
Wednesday September 30, 2020
Reven’s patented treatment platform for sepsis on track for testing COVID-19 patients
GOLDEN -- Reven Holdings, a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment platforms for cancer, viral... Read More
Tuesday September 15, 2020
IN Sponsors
Browse
Entrepreneurial by Nature
